| Medical user study on the BEMER 3000 - System | Abstract: Study period: May 1999 to December 2002. Objective: Identification of therapeutic effects of the BEMER signal in a multi-center medical user study. 

Tabular overview of

the principal disease groups evaluated

Approximately 220 medical facilities participated in the study. Participation was voluntary and was not compensated; only the the study devices were made available on loan.

Materials and Methods: Patient selection and treatment was done independently of the AFT by the treating physicians. Because the therapists wanted to critically test the effect of the BEMER 3000, they selected predominantly so-called conventional treatment-exhausted cases (patients who were treated using conservative therapies based on conventional medical knowledge but without therapeutic progress over a prolonged period).

Diagnoses were made using conventional medical standards. In polymorbid patients the different symptomologies were assessed individually. The respective symptom status or severity of the illness was classified on a five level evaluation scale. The use of the BEMER 3000 was done generally as a monotherapy in accordance with general therapeutic indications. Patients, who were taking medicinal products for the treatment of their specific symptoms, continued their medications in scope and dosage. Both previous therapeutic methods and the therapeutic parameters with respect to BEMER therapy, as well as the subjective and objective assessment of the course of therapy, were documented in the study protocol.

All treatments whose therapy period was at least four weeks and the cases in which previously satisfactory therapeutic results were obtained were included in the assessments.
The five level evaluation scale was reduced to the categories "symptom-free/good", "better" and "unchanged" better.

1116 records satisfied the evaluation criteria. Because a number of participating patients had several symptom pictures, there were 2031 cases.

42 different main disease groups with at least ten cases are listed. The average therapy period was six weeks.

Results of the patient-related evaluation:

851 patients (76%) are are symptom-free/good in at least one symptom

196 patient (18%) showed improvement in at least one symptom 

69 patients (6%) showed no health improvement within the treatment period

Results of the disease-related assessment:

65 % of treated illnesses were evaluated as "symptom-free/good" 

23 % of the illnesses showed improvement and in

12 % did not experience any change in the treatment period.